|
Market Closed -
Nasdaq
00:00:00 29/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 2.370 USD | -0.42% |
|
-6.32% | -73.22% |
Company Valuation: Atossa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 23.65 | - | - |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -68.97% | - | - |
| Enterprise Value (EV) | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 23.65 | 23.65 | 23.65 |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -68.97% | 0% | 0% |
| P/E | -8.89x | -2.52x | -3.67x | -4.72x | -2.19x | -0.63x | -0.85x | 0.87x |
| PBR | 1.47x | 0.57x | 1.22x | 1.69x | 1.92x | - | - | - |
| PEG | - | -0.2x | -0.3x | 0.3x | -0.1x | 0.09x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 0.2x |
| EV / Revenue | - | - | - | - | - | - | - | 0.2x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.65x | -0.62x | 0.48x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.7 | -3.15 | -3.6 | -3 | -4.04 | -3.747 | -2.783 | 2.715 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 118.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.52 | -27.69 | -31.38 | -27.62 | -37.14 | -36.12 | -38.03 | 49.46 |
| Net income 1 | -20.61 | -26.96 | -30.09 | -25.5 | -34.77 | -35.3 | -38.03 | 49.46 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 24.000 | 7.927 | 13.200 | 14.161 | 8.850 | 2.370 | 2.370 | 2.370 |
| Nbr of stocks (in thousands) | 8,442 | 8,442 | 8,354 | 8,387 | 8,611 | 9,979 | - | - |
| Announcement Date | 28/02/22 | 22/03/23 | 01/04/24 | 25/03/25 | 25/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.64x | - | - | - | 23.75M | |
| 17.08x | 6.33x | 12.4x | 1.75% | 63.48B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 54.55B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.59B | |
| 35.05x | 3.37x | 14.55x | -.--% | 44.75B | |
| 48.28x | 5.55x | 30.42x | -.--% | 41.62B | |
| -19.33x | 186.93x | -20.57x | -.--% | 39.91B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.47B | |
| 36.51x | 6.64x | 22.27x | -.--% | 26.7B | |
| 26.96x | 5.67x | 14.71x | -.--% | 23.36B | |
| Average | 24.13x | 26.33x | 15.57x | 0.34% | 38.05B | |
| Weighted average by Cap. | 26.55x | 25.23x | 15.68x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATOS Stock
- Valuation Atossa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
